ESSENTIAL HYPERTENSIVE PATIENTS;

Comparison of anti-hypertensive effect of candesartan cilexetil and amlodipine

Abstract

Objective: To compare blood pressure lowering effects of angiotensin II type I receptor blocker candesartan cilexetil in
comparison with calcium channel blocker amlodipine in essential hypertensive patients. Study design: Randomized, open-labeled,
prospective comparative study. Place and duration: The study was carried out in the department of pharmacology and therapeutics,
Basic Medical Sciences Institute (BMSI), Jinnah Post Graduate Medical Centre (JPMC), Karachi from July 2007 to January 2008.
Subjects and methods: In this study (80) newly diagnosed essential hypertensive patients were enrolled and divided into two groups
(DR1) and (DR2) respectively. DR1 patients received candesartan 16mg once a day and DR2 patients received Amlodipine 10mg once a
day for 3 months duration. Results: The mean systolic blood pressure of DRI was 162.23 on day 0 which decreased to 141.05 on day 90,
versus DR2 which decreased from 160.12 on day 0 to 140 on day 90. The mean diastolic blood pressure decreased significantly for DR 1
group from 99.87 mmHg to 87 to 89. mmHg, versus DR2 which decreased from 98.5 to 86.25. All values of blood pressure have been
taken in mmHg. The results of this study were observed statistically significant. Conclusions: Candesartan cilexetil is a newer and safer
alternative for the treatment of essential hypertensive patients in comparison to conventional antihypertensive treatment.